Juvenile Idiopathic Arthritis News and Research

RSS
Juvenile idiopathic arthritis (JIA) is the name given to a group of conditions characterized by joint inflammation or arthritis, occurring first before the age of 16.
Juvenile Arthritis patients may have difficulties achieving educational success

Juvenile Arthritis patients may have difficulties achieving educational success

DMARD not superior to oral therapy in long-term treatment of patients with JIA

DMARD not superior to oral therapy in long-term treatment of patients with JIA

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

High-dose glucocorticoids double risk of bacterial infections in children with JIA

High-dose glucocorticoids double risk of bacterial infections in children with JIA

High-dose steroids increase infection risk in children with juvenile idiopathic arthritis

High-dose steroids increase infection risk in children with juvenile idiopathic arthritis

Juvenile arthritis affected kids are at a high risk of cancer: Study

Juvenile arthritis affected kids are at a high risk of cancer: Study

Incident malignancy four times higher among children with JIA

Incident malignancy four times higher among children with JIA

Study evaluates JIA disease activity after treatment with etanercept

Study evaluates JIA disease activity after treatment with etanercept

New data from Novartis' ACZ885 Phase III study on SJIA

New data from Novartis' ACZ885 Phase III study on SJIA

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

DMARDs appear to be more effective for children with arthritis

DMARDs appear to be more effective for children with arthritis

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

Genentech receives FDA approval for Actemra to treat juvenile idiopathic arthritis

Genentech receives FDA approval for Actemra to treat juvenile idiopathic arthritis

New clinical practice guidelines developed for juvenile idiopathic arthritis

New clinical practice guidelines developed for juvenile idiopathic arthritis

Early diagnosis of juvenile idiopathic arthritis critical to avoid disability, deformity

Early diagnosis of juvenile idiopathic arthritis critical to avoid disability, deformity

Children with JIA face increase risk of developing cancer

Children with JIA face increase risk of developing cancer

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

Etanercept plus MTX improves height, weight, and BMI in children with juvenile idiopathic arthritis

Etanercept plus MTX improves height, weight, and BMI in children with juvenile idiopathic arthritis

Further trials needed to determine clinical application of Abatacept in SLE

Further trials needed to determine clinical application of Abatacept in SLE

Protagen AG announces € 10.0 Million for second round of finance totaling

Protagen AG announces € 10.0 Million for second round of finance totaling